#United States #Dividend #stock repurchase #Franklin Lakes #Becton Dickinson

BD Declares Dividend and Authorizes Increased Share Buyback

The Board of Directors of Becton, Dickinson and Company (BD), a leading name in global medical technology, has recently made significant announcements related to its financial strategies. On January 28, 2025, they officially declared a quarterly dividend amounting to $1.04 per common share. This dividend is set to be paid to all shareholders registered by March 10, 2025, with the payment date scheduled for March 31, 2025. Consequently, the annual dividend rate for the company now stands at an impressive $4.16 per share.

In conjunction with the dividend declaration, BD has reported that it has already executed a stock repurchase totaling $750 million during the current fiscal year 2025. This proactive approach to share buybacks highlights the company's commitment to returning value to its shareholders. In a further step to enhance this initiative, the board has authorized the repurchase of an additional 10 million shares of its common stock, which is separate from the shares made available under the previous authorization granted in 2021.

BD’s board maintains the flexibility to utilize various methods for share repurchases, including open market purchases and privately negotiated transactions. The timing and extent of these buybacks will be determined by management, taking into consideration several factors, such as the current market price of BD’s common stock, broader economic conditions, and other business considerations.

BD’s Commitment to Healthcare Innovation

BD is recognized as one of the largest global players in medical technology, advancing healthcare through innovative solutions and technology-driven strategies. The company dedicates itself to enhancing medical discovery, diagnostics, and patient care delivery. With over 70,000 employees worldwide, BD is passionate about improving the efficacy and safety of healthcare while assisting those on the frontline of health services.

BD continues to innovate in its product offerings, supporting hospital staff and healthcare professionals with advanced tools and services designed to facilitate better patient outcomes. The company's vast reach extends to nearly every country, enabling it to tackle some of the world's most pressing health challenges.

The strategic decisions made by BD’s board signal not only a robust financial health outlook but also reflect the company’s ongoing dedication to increasing shareholder value. The upcoming share buybacks and consistent dividend payments are intended to further instill investor confidence and reinforce BD's position in the competitive healthcare landscape.

For more insights into BD’s ventures and innovations, and to remain updated on future financial decisions, interested stakeholders are encouraged to visit their official website bd.com or connect with them on social media platforms like LinkedIn and Twitter (@BDandCo).

In summary, BD's declarations of dividends and the authorization of additional share repurchases exemplify a solid financial strategy aimed at enhancing shareholder value, while also supporting the company’s vision of improving health worldwide.